Sequential Therapy of Atorvastatin Improve Outcomes of ST-elevated Acute Myocardial Infarction
NCT ID: NCT01997294
Last Updated: 2016-10-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
1200 participants
INTERVENTIONAL
2013-01-31
2017-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Intensive Statin Treatment in Chinese Coronary Artery Disease Patients Undergoing PCI
NCT01293097
Intensive Statin Treatment for STEMI Patients Undergoing Primary PCI
NCT01033058
Intensive Lipid Lowering Treatment in Non-ST-elevation Acute Coronary Syndrome (NSTE-ACS) Patients
NCT01040936
Efficacy of High Dose atorvaSTATIN Loading Before Primary Percutaneous Coronary Intervention in ST Elevation Myocardial Infarction (STATIN STEMI)
NCT00808717
The Clinical Effect of Intensive Statin Therapy in STEMI Patients Before Emergency PCI
NCT01334671
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
sequential therapy group
80mg atorvastatin before primary PCI (PPCI) followed by 40mg/d for 7 days after PPCI followed by 20mg/d for 1 year
Sequential therapy of atorvastatin
80mg atorvastatin before PPCI and 40mg/d for 7 days after PPCI
Usual Therapy of atorvastatin
20mg/d before and after PPCI for 1 year
Sequential therapy of atorvastatin
80mg atorvastatin before PPCI and 40mg/d for 7 days after PPCI
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Sequential therapy of atorvastatin
80mg atorvastatin before PPCI and 40mg/d for 7 days after PPCI
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosised as acute myocardial infarction
* Time frame less than 12 hours since the occurance of chest pain
* Aggred to receive sirolimus-eluted coronary stents
* Patients willing to accepte follow-up
Exclusion Criteria
* Allegy to any products that will be used during PPCI
* Disagreed to receive PPCI and other related therapy
* Existing sever liver dysfuntion that statins can not be used according to the guildlines
* Sever kidney dysfunction (creatinine \>3mg/dl or eGFR\<30ml/min)
* Sever left ventricular dysfunction (Killip grade 3)
* Patients are currently taking medicine that may influence the use of statin
* Patients with a history of alcohol abuse or durg abuse
* Woman during pregnancy or lactation
* Patients who has attended other clinical trials
* Patients who has received PCI or CABG previously
* Patients who can not agree to accept study protocol
* Other conditions that may not sutible for the current study
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Zhang Qi, MD
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Zhang Qi, MD
Visa Chief of Department of Cardiology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Weifeng Shen, MD. PhD.
Role: STUDY_DIRECTOR
Institute of Cardiovascular Diseases, School of Medicine, Shanghai Jiao Tong University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ruijin Hospital, Dept. of Cardiology
Shanghai, Shanghai Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2011BAI11B05
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
RJH20130115
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.